Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769210 · ClinicalTrials.gov registry record · Early Phase 1
The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure
A Early Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT00769210 is a Early Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 12 participants.
The verdict
NCT00769210, a Early Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Our proposed research will examine whether treatment with simvastatin alters expression and activity of monocyte TF, whether polymorphisms in the TF gene alter the therapeutic effect and what effect treatment has on inflammatory markers in heart failure. The results of this study may assist in tailoring statin therapy to specific characteristics, such as inflammatory state, of heart failure patients. If treatment with simvastatin significantly lowers TF expression, this may reduce the risk of thromboembolic events in patients with heart failure, thus reducing mortality and morbidity. If the treatment effect varies based on the TF genotype, this may define an identifiable population in whom statin therapy may be more beneficial than the population as a whole.
Interventions
- DRUG Simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769210
The ClinicalTrials.gov registry entry for NCT00769210 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simvastatin is the first listed.
NCT00769210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00769210 about?
NCT00769210 is a clinical study titled "The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure". Our proposed research will examine whether treatment with simvastatin alters expression and activity of monocyte TF, whether polymorphisms in the TF gene alter the therapeutic effect and what effect treatment has on inflammatory markers in heart failure. The results of this study may assist in tailo...
What is the current status of trial NCT00769210?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2005-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00769210?
The interventions under investigation include: Simvastatin (DRUG).
Who is sponsoring clinical trial NCT00769210?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.